The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

The new breast cancer screening guidelines are not enough to save Black women

A breast surgical oncologist and breast radiologist weigh in

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The U.S. Preventive Services Task Force’s new guidelines to offer mammography from age 40 will save many lives.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Vivian Jolley Bea, MD
Chief, Breast Surgical Oncology,
Director, Breast Program, New York Presbyterian Brooklyn Methodist Hospital; Assistant professor of surgery, Weill Cornell Medicine
Kemi Babagbemi, MD
Vice chair, Diversity, Equity, and Inclusion,
Department of Radiology, Associate professor of clinical radiology, Weill Cornell Medicine; Associate attending radiologist, New York-Presbyterian Hospital
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Genentech’s Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds

Genentech announced positive topline results from the overall survival analysis of the phase III INAVO120 study investigating Itovebi (inavolisib) in combination with palbociclib (Ibrance) and fulvestrant for people with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. 
Drugs & Targets

FDA approves Enhertu as first HER2-directed therapy for breast cancer

FDA approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by the FDA approved test, that has progressed on one or more endocrine therapies in the metastatic setting.
Clinical Roundup

SWOG study: Statistical tool provides more accurate estimates of recurrence risk and chemotherapy benefit in breast cancer

A new statistical tool that combines multiple clinical and pathologic factors with a patient’s 21-gene Oncotype DX Breast Recurrence Score result provides more accurate estimates about that patient’s breast cancer prognosis and their potential benefit from chemotherapy than either the Recurrence Score result or clinical factors alone, a SWOG Cancer Research study found.

ACS report: Cancer mortality continues to drop despite rising incidence in women

Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% higher in 2002. In 2021, for the first time, lung cancer incidence was higher in women under 65 than in men. 
By Yiqing Wang
Byline
Vivian Jolley Bea, MD
Chief, Breast Surgical Oncology,
Director, Breast Program, New York Presbyterian Brooklyn Methodist Hospital; Assistant professor of surgery, Weill Cornell Medicine
Kemi Babagbemi, MD
Vice chair, Diversity, Equity, and Inclusion,
Department of Radiology, Associate professor of clinical radiology, Weill Cornell Medicine; Associate attending radiologist, New York-Presbyterian Hospital
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account